{
  "docId": "019de073-8568-725b-9a17-a64262808fc8",
  "docSlug": "d872feff7a8967ecac479e446ba0e3da",
  "documentTitle": "Context Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "context-therapeutics",
  "authorName": "Context Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 25,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 10,
  "notes": "The table highlights the prevalence column with an orange box.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8568-725b-9a17-a64262808fc8/17",
  "deckHref": "/decks/019de073-8568-725b-9a17-a64262808fc8",
  "deckJsonHref": "/decks/019de073-8568-725b-9a17-a64262808fc8.json",
  "deckAnchorHref": "/decks/019de073-8568-725b-9a17-a64262808fc8#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.22,
        "x": 0.735,
        "y": 0.015
      },
      "kind": "legend",
      "text": "CLDN6xCD3 Bispecific Antibody Program",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a4aea57-ffe8-4379-8e4b-e517616e82d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.84,
        "x": 0.08,
        "y": 0.16
      },
      "kind": "table",
      "text": "Cancer, Prevalence (IHC, RNAseq), Reference. Testicular 95% Reinhard 2020. Ovarian 54-55% Reinhard 2020, Wang 2013. Gastric 13-55% Gao 2013, Kohmoto 2020, Lin 2013. NSCLC 6.5-50% Micke 2014, Reinhard 2020, Soini 2022, Wang 2015.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d09899a-0907-48ca-8890-bb8e7438ef7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.345,
        "x": 0.048,
        "y": 0.075
      },
      "kind": "title",
      "text": "CLDN6 Prevalence in Cancer",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "780b201f-b4a6-4f33-86ad-e07f5b0c6717",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "f70d1c5b-7f56-43f7-952f-e37a88979b33",
      "evidence": "table/data: Cancer, Prevalence (IHC, RNAseq), Reference. Testicular 95% Reinhard 2020. Ovarian 54-55% Reinhard 2020, Wang 2013. Gastric 13-55% Gao 2013, Kohmoto 2020, Lin 2013. NSCLC 6.5-50% Micke 2014, Reinhard 2020, So",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f563f0a-bba6-40be-8cea-242e5c29e44d",
      "evidence": "Slides 11-24 outline the potential of ONA-XR and CLDN6xCD3 Bispecific Antibody Program",
      "position": 0,
      "objective": "Highlight the benefits of investment in Context Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}